Separation of Isomeric Tau Phosphopeptides from Alzheimer's Disease Brain by Cyclic Ion Mobility Mass Spectrometry
- PMID: 36706338
- PMCID: PMC10017020
- DOI: 10.1021/jasms.2c00289
Separation of Isomeric Tau Phosphopeptides from Alzheimer's Disease Brain by Cyclic Ion Mobility Mass Spectrometry
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder of increasing concern. It belongs to diseases termed tauopathies which are characterized by inclusions of abnormally hyperphosphorylated and truncated forms of the protein tau. Studies of tauopathies often focus on detection and characterization of these aberrant tau proteoforms, in particular the phosphorylation sites, which represent a significant analytical challenge for example when several phosphosites can be present on the same peptide. Such isomers can even be difficult to fully separate chromatographically. Since recently introduced cyclic ion mobility-mass spectrometry can offer different selectivity, we have investigated the closely positioned phosphorylation sites S214, T212, and T217 of a tryptic peptide from proline rich region of tau-TPSLPTPPTREPK. The conformational heterogeneity of the isomeric peptides in the gas phase hindered their separation due to their overlapping arrival time distributions. Increasing the resolution of the analysis alone is insufficient to distinguish the peptides in a mixture typical of patient samples. We therefore developed a method based on a combination of collision-induced dissociation, isomeric product ions (m/z 677) mobility separation and post-mobility dissociation to aid in analyzing the isomeric phosphopeptides of tau in diseased brain extract. For all three isomers (T212, S214, and T217), the ion mobility signal of the ion at m/z 677 was still observable at the concentration of 0.1 nmol/L. This work not only offers insights into the phosphorylation of tau protein in AD but also provides an analytical workflow for the characterization of challenging pathological protein modifications in neurodegenerative diseases.
Conflict of interest statement
The authors declare the following competing financial interest(s): R.H., D.C.-S., and A.M. are employees of Waters corporation that is a producer of cyclic ion mobility (Select Series Cyclic IMS Spectrometer).
Figures




Similar articles
-
Development of immunoprecipitation - two-dimensional liquid chromatography - mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients.J Chromatogr A. 2021 Aug 16;1651:462299. doi: 10.1016/j.chroma.2021.462299. Epub 2021 May 28. J Chromatogr A. 2021. PMID: 34107398
-
Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain.J Neurochem. 1994 Oct;63(4):1416-25. doi: 10.1046/j.1471-4159.1994.63041416.x. J Neurochem. 1994. PMID: 7931292
-
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.Ann Clin Transl Neurol. 2021 Sep;8(9):1817-1830. doi: 10.1002/acn3.51435. Epub 2021 Aug 2. Ann Clin Transl Neurol. 2021. PMID: 34342183 Free PMC article.
-
Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.J Alzheimers Dis. 2019;67(1):13-33. doi: 10.3233/JAD-180868. J Alzheimers Dis. 2019. PMID: 30507581 Review.
-
Post-translational modifications of tau protein: implications for Alzheimer's disease.Neurochem Int. 2011 Mar;58(4):458-71. doi: 10.1016/j.neuint.2010.12.023. Epub 2011 Jan 6. Neurochem Int. 2011. PMID: 21215781 Review.
Cited by
-
Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease.Biosensors (Basel). 2023 Jul 17;13(7):742. doi: 10.3390/bios13070742. Biosensors (Basel). 2023. PMID: 37504140 Free PMC article. Review.
-
Cyclic Ion Mobility of Isomeric New Psychoactive Substances Employing Characteristic Arrival Time Distribution Profiles and Adduct Separation.J Am Soc Mass Spectrom. 2024 Aug 7;35(8):1733-1742. doi: 10.1021/jasms.4c00127. Epub 2024 Jul 1. J Am Soc Mass Spectrom. 2024. PMID: 38949154 Free PMC article.
-
Multi-Pass Arrival Time Correction in Cyclic Ion Mobility Mass Spectrometry for Imaging and Shotgun Lipidomics.ACS Meas Sci Au. 2024 Dec 27;5(1):109-119. doi: 10.1021/acsmeasuresciau.4c00077. eCollection 2025 Feb 19. ACS Meas Sci Au. 2024. PMID: 39991034 Free PMC article.
-
Unraveling the Structure and Dynamics of Ac-PHF6-NH2 Tau Segment Oligomers.ACS Chem Neurosci. 2024 Sep 18;15(18):3391-3400. doi: 10.1021/acschemneuro.4c00404. Epub 2024 Aug 30. ACS Chem Neurosci. 2024. PMID: 39215387 Free PMC article.
-
Exploring the Aggregation Propensity of PHF6 Peptide Segments of the Tau Protein Using Ion Mobility Mass Spectrometry Techniques.Anal Chem. 2024 Apr 2;96(13):5115-5124. doi: 10.1021/acs.analchem.3c04974. Epub 2024 Mar 22. Anal Chem. 2024. PMID: 38517679 Free PMC article.
References
-
- Fossati S.; Ramos Cejudo J.; Debure L.; Pirraglia E.; Sone J. Y.; Li Y.; Chen J.; Butler T.; Zetterberg H.; Blennow K.; de Leon M. J. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer’s disease. Alzheimers Dement (Amst) 2019, 11 (1), 483–492. 10.1016/j.dadm.2019.05.001. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical